AAPG Stock Analysis: Buy, Sell, or Hold?
AAPG - Ascentage Pharma Group International American Depository Shares
$26.05
2.18 (9.13%)
▲
5d:
+16.4%
30d:
+10.1%
90d:
-1.66%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Apr 01, 2026
0d
Get Alerted When AAPG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AAPG shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AAPG shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AAPG is currently trading at $26.05, which is considered extended relative to its 30-day fair value range of $21.93 to $24.81.
Technical Outlook: Technically, AAPG is in a strong downtrend. The price is approaching resistance at $26.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.1% recently.
Market Sentiment: AAPG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.14 (+105.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AAPG is in a strong downtrend. The price is approaching resistance at $26.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.1% recently.
Market Sentiment: AAPG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.14 (+105.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$21.93 -
$24.81
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.1%)
- BULLISH: Trading 105.9% below Wall St target ($49.14)
Fair Price Analysis
30-Day Fair Range
$21.93 -
$24.81
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$19.11
Resistance Level
$26.40
Current Trend
Strong Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-49.66
Wall Street Target
$49.14
(+105.9%)
Revenue Growth (YoY)
-71.6%
Profit Margin
-296.8%
Share & Embed Analysis
Last updated: April 01, 2026 3:02 PM ET
Data refreshes hourly during market hours. Next update: 4:02 PM
Data refreshes hourly during market hours. Next update: 4:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AAPG showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 66 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 52 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 62 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 48 HOLD |
